Acute myeloid leukemia (AML) is a malignant expansion of immature cells in the bone marrow. Although chemotherapeutic treatments containing cytosine arabinoside (Ara-C) typically result in dramatic remissions, resistance to chemotherapy frequently occurs. Patients presenting with Ara-C-resistant AML have a reduction in the active metabolized form of Ara-C (Ara-CTP), but the mechanisms responsible for this reduction are still being investigated. In previously published work, two AML cell lines (B117P and B140P), derived from BXH-2 strain mouse leukemias, were subjected to increasing concentrations of Ara-C to create two highly resistant derivatives (B117H and B140H) that tolerate Ara-C concentrations B800 times that of their parental lines. 1 In this study, gene expression microarrays were conducted to determine the expression changes common to both sets of cell lines. The results were verified by quantitative PCR (qPCR) and the specificity of drug resistance was evaluated.
The parental cell lines (B117P and B140P) are markedly different phenotypically and yet their response to Ara-C is about the same with similar 50% inhibitory concentrations (IC 50 ). B117P grows 2.3 times faster than B140P (data not shown), and they have differences in gene expression patterns, as detected by microarray analysis. Although CD34 has not been found to be associated with any particular AML subtype or to be prognostically significant, B117P and B117H highly express Cd34 whereas B140P and B140H do not (a 183-fold difference). Furthermore, the level of myeloperoxidase (Mpo) is 34-fold greater in the B117P cells when compared with the B140P cells. Despite these differences, both cell lines showed some common changes in gene expression on selection for Ara-C resistance. Microarray gene expression analysis to compare differences between the parental cell lines (B117P and B140P) and their highly resistant derivatives (B117H and B140H) was performed on 12 RNA isolations (3 isolations for each cell line from different passages) using Affymetrix (Santa Clara, CA, USA) Mouse Genome 430 2.0 Arrays containing 45 101 murine oligonucleotide sequences. The detection values were processed using Genedata Expressionist software (Genedata AG, Basel, Switzerland) using the robust multiarray average normalization technique. The raw data are available online at http:// www.ncbi.nlm.nih.gov/geo/ (accession number GSE18322). Group t-test analysis was used to compare the B117P cells to the B117H cells, and the B140P cells to the B140H cells. Only expression changes greater than 2.0-fold with P-values o0.001 were considered. One hundred and twenty differentially expressed probe sets representing 104 genes were obtained when comparing B140H to B140P. Two hundred and eighty six differentially expressed probe sets representing 239 genes were obtained when comparing B117H to B117P. In Table 1 those genes with consistent expression changes (42.0-fold) on selection for Ara-C resistance in both cell lines are listed.
The deoxycytidine kinase (Dck) gene mRNA level was altered to a greater extent than any other single gene. Starting levels of Dck expression were similar in both the B117P and B140P parental cell lines. However, the Dck levels in the B117H cells were near zero, whereas the Dck levels in B140H cells were decreased 8.0-fold compared to B140P. The probe sets used to measure Dck expression targeted the 3 0 -UTR of Dck. Expression changes for the Dck gene were confirmed by qPCR analysis using the Eppendorf (Hamburg, Germany) Mastercycler ep realplex. PCR primers were designed to target the 3 0 end of the Dck transcript. Rps9, a gene that is expressed at moderate and consistent levels across all four cell lines, was used to normalize the results. The qPCR analysis confirmed the altered expression levels found in the microarray ( Figure 1 ). DCK encodes deoxycytidine kinase, which phosphorylates deoxyribonucleosides including deoxycytidine, deoxyguanosine and deoxyadenosine. DCK performs the rate-limiting step in Ara-C metabolic activation, which is monophosphosphorylation after import of Ara-C through the SLC29A1 nucleoside transporter. Thus, downregulation of this kinase would be expected to lead Table 1 Common gene expression changes between Ara-C-resistant cell lines and their Ara-C-sensitive parental lines (42.0-fold) to resistance to Ara-C. Indeed, polymorphisms in the human DCK gene have been associated with patient's response to AML chemotherapies containing Ara-C, 2 and expression of alternatively spliced isoforms of DCK are found in some Ara-C-resistant AML patients. 3 A recent paper described alterations in DCK expression in a human AML cell line selected for resistance to Ara-C in vitro. 4 These investigators also noted that primary human AML samples differ in the level of DCK transcript, and that these differences may relate to Ara-C sensitivity, at least as measured in an in vitro assay.
Drug assays were conducted on all four cell lines to determine if Ara-C resistance conferred drug resistance to other chemotherapy drugs. There were no changes in response to daunorubicin or etoposide (data not shown). However, there was a significant change in the response to decitabine in both sets of cells, with a greater than 800-fold increase in IC 50 values in Ara-Cresistant derivatives compared to parental cell lines (Figure 2 ). Both Ara-C and decitabine are deoxycytidine analogs, and are triphosphorylated by the same kinases (including Dck). However, their methods of interfering with cell proliferation are entirely different. Once triphosphorylated, Ara-C is incorporated into DNA during replication, blocking polymerase and topoisomerase activity, whereas decitabine inhibits DNA methyltransferase activity. Because the change in resistance to both Ara-C and decitabine are comparable, this supports the hypothesis that the Ara-C drug resistance of the B117H and B140H cells is driven specifically by the downregulation of Dck.
However, there are other changes taking place in the cells that may have a supporting role in the development of drug resistance. For example, the urea transporter Slc14a1 is upregulated in both sets of Ara-C-resistant cells. This suggests that the Ara-C-resistant cells are producing more urea than their Ara-C-sensitive parental cells. Downregulation of Dck would also interfere with the cells ability to get deoxycytidines through the salvage pathway. So, one possible explanation for this increase in urea is that the Ara-C-resistant cells are deriving the building blocks for de novo synthesis of cytosine from the degradation of thymidine. Urea is a by-product of the thymidine degradation process.
Manipulation of the Wnt pathway may also be involved in Ara-C resistance. Dab2, an adaptor protein that stabilizes Axin, and thus blocks Wnt signaling, 5 is downregulated in both Ara-C-resistant cell lines, suggesting an increase of Wnt/bcatenin signaling may be present in the Ara-C-resistant derivatives.
Another gene of particular interest is Ifitm1, which was significantly downregulated in both Ara-C-resistant cell lines. Ifitm1, also called Leu13, is an interferon-induced antiproliferative transmembrane protein. Lower levels of IFITM1 expression have been shown to correlate with decreased survival in chronic myeloid leukemia. 6 A decrease in IFITM1 expression in esophageal squamous cell carcinoma has been shown to correlate with increased resistance to cis-platinum.
Because the gene expression patterns of B117P and B140P cells are so different, analysis of gene expression changes for each cell line on selection for Ara-C may provide clues for identifying additional drug resistance genes (Tables 2  and 3 ). For example, in the B140H cells, there was a 36-fold downregulation of Spint2, which has been characterized as a tumor suppressor gene in medulloblastoma.
7 B117H cells have upregulated the neuregulin-4 (Nrg4) gene transcript 10-fold. Nrg4 can bind to and activate epidermal growth factor receptor family receptors and so their activation could contribute to the Ara-C-resistant phenotype in this cell line perhaps by activation of the RAS/MAPK pathway that has been shown to modulate Ara-C responsiveness. S100a10 gene expression is dramatically downregulated in B140H cells, and the product of this gene interacts with Annexin-11, which has been described as an anti-apoptotic protein involved in chemotherapy resistance. 8 Further studies are underway to determine the mechanisms behind the reduction in Dck expression and to identify whether the expression changes of other genes identified by the microarray analysis are required by the cells to compensate for loss of Dck expression or participate in the development of Ara-C resistance by other mechanisms. Drugs targeting the pathways that can cooperate with Dck downregulation to allow Ara-C resistance may be useful for preventing the selection of Ara-C-resistant clones in patients. -2 B117P B140H B140P B117H Figure 2 Response of Ara-C-resistant cell lines and their parental lines to decitabine. CellTiter 96 AQ ueous Non-Radioactive Cell Proliferation Assay (Promega Corp, Madison, WI, USA) was used to measure inhibitory concentration using previously described methods. 1 Each cell line was evaluated three or more times. IC 50 was calculated using CalcuSyn software (Biosoft, Cambridge, UK) and had r-values 40.95. P-values resulting from t-test comparisons of Ara-Cresistant cells to their parental lines were o0.001. Table 3 Tenfold gene expression changes comparing Ara-C-resistant B140H cells to B140P parental cells Table 2 Tenfold gene expression changes comparing Ara-C-resistant B117H cells to B117P parental cells
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